Cornely, Oliver A.

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 1,556

ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients

Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection

Antifungal resistance and susceptibilityOcular Infections and Treatments

Cited by 1,217

Tackling the emerging threat of antifungal resistance to human health

Fisher, M. C., Alastruey-Izquierdo, A., Berman, J., Bicanic, T., Bignell, E. M., Bowyer, P., Bromley, M., Brüggemann, R., Garber, G., Cornely, O. A., et al. (2022) · Nature Reviews Microbiology

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 1,179

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., et al. (2016) · The Lancet

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 1,001

Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial

Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 692

COVID-19 Associated Pulmonary Aspergillosis

Koehler, P., Cornely, O. A., Böttiger, B. W., Dusse, F., Eichenauer, D. A., Fuchs, F., Hallek, M., Jung, N., Klein, F., Persigehl, T., et al. (2020) · Mycoses

Antifungal resistance and susceptibilityCOVID-19 Clinical Research Studies

Cited by 547

Combination Antifungal Therapy for Invasive Aspergillosis: A Randomized Trial

Marr, K. A., Schlamm, H. T., Herbrecht, R., Rottinghaus, S. T., Bow, E. J., Cornely, O. A., Heinz, W. J., Jagannatha, S., Koh, L. P., Kontoyiannis, D. P., et al. (2015) · Annals of Internal Medicine

Antifungal resistance and susceptibilityNeutropenia and Cancer Infections

Cited by 514

Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against Candida albicans

Bacher, P., Hohnstein, T., Beerbaum, E., Röcker, M., Blango, M. G., Kaufmann, S., Röhmel, J., Eschenhagen, P., Grehn, C., Seidel, K., et al. (2019) · Cell

Psoriasis: Treatment and PathogenesisT-cell and B-cell Immunology

Cited by 473

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin

Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs

Antifungal resistance and susceptibilityFungal Plant Pathogen Control

Cited by 467

ESCMID guideline for the diagnosis and management of Candida diseases 2012: diagnostic procedures.

Cuenca-Estrella, M., Verweij, P. E., Arendrup, M. C., Arikan-Akdagli, S., Bille, J., Donnelly, J. P., Jensen, H. E., Lass-Flörl, C., Richardson, M. D., Akova, M., et al. (2012) · Clinical Microbiology and Infection

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 386

Invasive Aspergillosis: Epidemiology, Diagnosis and Management in Immunocompromised Patients

Maschmeyer, G., Haas, A., & Cornely, O. A. (2007) · Drugs

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 366

ESCMID guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.

Hope, W. W., Castagnola, E., Groll, A. H., Roilides, E., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Cornely, O. A., et al. (2012) · Clinical Microbiology and Infection

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 360

Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis

Koehler, P., Stecher, M., Cornely, O. A., Koehler, D., Vehreschild, M. J. G. T., Bohlius, J., Wisplinghoff, H., & Vehreschild, J. J. (2019) · Clinical Microbiology and Infection

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 336

ESCMID guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT)

Ullmann, A. J., Akova, M., Herbrecht, R., Viscoli, C., Arendrup, M. C., Arikan-Akdagli, S., Bassetti, M., Bille, J., Calandra, T., Castagnola, E., et al. (2012) · Clinical Microbiology and Infection

Antifungal resistance and susceptibilityNeutropenia and Cancer Infections

Cited by 334

Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19

Bacher, P., Rosati, E., Esser, D., Martini, G. R., Saggau, C., Schiminsky, E., Dargvainiene, J., Schröder, I., Wieters, I., Khodamoradi, Y., et al. (2020) · Immunity

SARS-CoV-2 and COVID-19 ResearchT-cell and B-cell Immunology

Cited by 314

Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project

Bassetti, M., Giacobbe, D. R., Vena, A., Trucchi, C., Ansaldi, F., Antonelli, M., Adamkova, V., Alicino, C., Almyroudi, M.-P., Atchade, E., et al. (2019) · Critical Care

Antifungal resistance and susceptibilityNosocomial Infections in ICU

Cited by 270

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

Thompson, G. R., Soriano, A., Cornely, O. A., Kullberg, B. J., Kollef, M., Vazquez, J., Honore, P. M., Bassetti, M., Pullman, J., Chayakulkeeree, M., et al. (2023) · The Lancet

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 192

Breakthrough invasive fungal infections: Who is at risk?

Jenks, J. D., Cornely, O. A., Chen, S. C. ‐., Thompson, G. R., & Hoenigl, M. (2020) · Mycoses

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 191

Diagnosing COVID-19-associated pulmonary aspergillosis

Verweij, P. E., Gangneux, J.-P., Bassetti, M., Brüggemann, R. J. M., Cornely, O. A., Koehler, P., Lass-Flörl, C., van de Veerdonk, F. L., Chakrabarti, A., & Hoenigl, M. (2020) · The Lancet Microbe

Antifungal resistance and susceptibilityCOVID-19 Clinical Research Studies

Cited by 181

Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study

Hoenigl, M., Salmanton-García, J., Egger, M., Gangneux, J.-P., Bicanic, T., Arikan-Akdagli, S., Alastruey-Izquierdo, A., Klimko, N., Barac, A., Özenci, V., et al. (2023) · The Lancet Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 152

Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study

Cordonnier, C., Rovira, M., Maertens, J., Olavarria, E., Faucher, C., Bilger, K., Pigneux, A., Cornely, O. A., Ullmann, A. J., Bofarull, R. M., et al. (2010) · Haematologica

Antifungal resistance and susceptibilityNeutropenia and Cancer Infections

Cited by 137

Attributable mortality of candidemia – Results from the ECMM Candida III multinational European Observational Cohort Study

Salmanton-García, J., Cornely, O. A., Stemler, J., Barać, A., Steinmann, J., Siváková, A., Akalin, E. H., Arikan-Akdagli, S., Loughlin, L., Toscano, C., et al. (2024) · Journal of Infection

Antifungal resistance and susceptibilityInfective Endocarditis Diagnosis and Management

Cited by 127

Phase II Dose Escalation Study of Caspofungin for Invasive Aspergillosis

Cornely, O. A., Vehreschild, J. J., Vehreschild, M. J. G. T., Würthwein, G., Arenz, D., Schwartz, S., Heussel, C. P., Silling, G., Mahne, M., Franklin, J., et al. (2011) · Antimicrobial Agents and Chemotherapy

Antifungal resistance and susceptibilityAntibiotics Pharmacokinetics and Efficacy

Cited by 93

Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study

Koehler, P., Hamprecht, A., Bader, O., Bekeredjian-Ding, I., Buchheidt, D., Doelken, G., Elias, J., Haase, G., Hahn-Ast, C., Karthaus, M., et al. (2017) · International Journal of Antimicrobial Agents

Antifungal resistance and susceptibilityNeutropenia and Cancer Infections

Cited by 91